The Lundquist Institute
Devinderjit Moudgil, Ph.D., is currently serving as a Business Development Officer at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center since January 2023. Previously, Moudgil worked as a Research Associate and Commercialization Research Associate at the University of Windsor from October 2019 to January 2023, facilitating communication between faculty and the tech transfer office. Moudgil held the position of AUTM Technology Transfer Fellow during 2020-2021, gaining formal training and mentorship in technology transfer. Additional experience includes research roles at Windsor Regional Hospital, market analysis and client engagement at Canadian Immigration Connections, and a Graduate Student Research Assistant position at Case Western Reserve University. Moudgil earned a Ph.D. in Experimental Oncology from the University of Alberta and has extensive research experience in oncology and developmental biology.
This person is not in any teams
This person is not in any offices
The Lundquist Institute
The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), is an engine of innovation with a global reach and a 67-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, The Lundquist Institute is poised to serve as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous orphan diseases, and is responsible for three FDA-approved drugs including the first approved treatment for sickle cell disease in 20 years.